Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

References

• Novak MJU, Tabrizi SJ. Clinical review Huntington’s disease. BMJ. 2010;340:34–40.
   Google Scholar
• Baig SS, Strong M, Quarrell OWJ. The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodegener Dis Manag. 2016;6:331–343.
   PubMed Web of Science ®Google Scholar
• Macdonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983.
   PubMed Web of Science ®Google Scholar
• Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev. 2010;10:905–981.
   Google Scholar
• Sorolla MA, Rodríguez-Colman MJ, Vall-Llaura N, et al. Protein oxidation in Huntington disease. BioFactors. 2012;38:173–185.
   PubMed Web of Science ®Google Scholar
• Perutz MF. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 1999;24:58–63.
   PubMed Web of Science ®Google Scholar
• Kuemmerle S, Gutekunst C, Klein AM, et al. Huntingtin aggregates may not predict neuronal death in Huntington’s Ddsease. Ann Neurol. 1999;46:842–849.
   PubMed Web of Science ®Google Scholar
• Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810.
   PubMed Web of Science ®Google Scholar
• Mazarei G, Budac DP, Lu G, et al. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J Neurochem. 2013;127:852–867.
   PubMed Web of Science ®Google Scholar
• Ehrlich ME. Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics. 2012;9:270–284.
   PubMed Web of Science ®Google Scholar
• Yager LM, Garcia AF, Wunsch AM, et al. The ins and outs of the striatum: role in drug addiction. Neuroscience. 2015;301:529–541.
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Effects of acetylcholine in the striatum: recent insights and therapeutic implications. Neurology. 2012;79:247–281.
   Web of Science ®Google Scholar
• Veres G, Molnár M, Zádori D, et al. Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington’s disease. Pharmacol Biochem Behav. 2015;132:115–124.
   PubMed Web of Science ®Google Scholar
• Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci. 1992;108:80–87.
   PubMed Web of Science ®Google Scholar
• Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature. 1976;263:244–246.
   PubMed Web of Science ®Google Scholar
• Beal MF, Kowall NW, Ellison DW, et al. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature. 1986;321:168–171.
   PubMed Web of Science ®Google Scholar
• Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72:411–412.
   PubMed Web of Science ®Google Scholar
• Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington’s disease. Science. 1988;241:981–983.
   PubMed Web of Science ®Google Scholar
• Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med. 1990;322:1293–1298.
   PubMed Web of Science ®Google Scholar
• Stoy N, Mackay GM, Forrest CM, et al. Tryptophan metabolism and oxidative stress in patients with Huntington’s disease. J Neurochem. 2005;93:611–623.
   PubMed Web of Science ®Google Scholar
• Zádori D, Geisz A, Vámos E, et al. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington’s disease. Pharmacol Biochem Behav. 2009;94:148–153.
   PubMed Web of Science ®Google Scholar
• Stahl WL, Swanson PD. Biochemical abnormalities in Huntington’s chorea brains. Neurology. 1974;24:813–819.
   PubMedGoogle Scholar
• Greene JG, Porter RHP, Eller RV, et al. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum. J Neurochem. 1993;61:1151–1154.
   PubMed Web of Science ®Google Scholar
• Jenkins BG, Koroshetz WJ, Beal MF, et al. Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology. 1993;43:2689–2695.
   PubMed Web of Science ®Google Scholar
• Koroshetz WJ, Jenkins BG, Rosen BR, et al. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41:160–165.
   PubMed Web of Science ®Google Scholar
• Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett. 2001;315:149–153.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of Coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci. 2002;22:1592–1599.
   PubMed Web of Science ®Google Scholar
• Group THS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.
   PubMed Web of Science ®Google Scholar
• Wyttenbach A, Sauvageot O, Carmichael J, et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet. 2002;11:1137–1151.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Cleeter MWJ, Xuereb J, et al. Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol. 1999;45:25–32.
   PubMed Web of Science ®Google Scholar
• Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60:161–172.
   PubMed Web of Science ®Google Scholar
• Simmons DA, Casale M, Alcon B, et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia. 2007;55:1074–1084.
   PubMed Web of Science ®Google Scholar
• Singhrao SK, Neal JW, Morgan BP, et al. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp Neurol. 1999;159:362–376.
   PubMed Web of Science ®Google Scholar
• Forrest CM, Mackay GM, Stoy N, et al. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington’s disease. J Neurochem. 2010;112:112–122.
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17:496–502.
   PubMed Web of Science ®Google Scholar
• Leklem JE. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr. 1971;24:659–672.
   PubMed Web of Science ®Google Scholar
• Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119:197–209.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res. 1998;23:635–644.
   PubMed Web of Science ®Google Scholar
• Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Suppl. 1974;136:1–186.
   PubMedGoogle Scholar
• Han Q, Cai T, Tagle DA, et al. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci. 2010;67:353–368.
   Web of Science ®Google Scholar
• Okuno E, Nakamura M, Schwarcz R. Two kynurenine aminotransferases in human brain. Brain Res. 1991;542:307–312.
   PubMed Web of Science ®Google Scholar
• Elmslie KS, Yoshikami D. Effects of kynurenate on root potentials evoked by synaptic activity and amino acids in the frog spinal cord. Brain Res. 1985;330:265–272.
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Schwarcz R. Kynurenic acid as an antagonist of α7nicotinic Acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013;85:1027–1032.
   PubMed Web of Science ®Google Scholar
• Marchi M, Risso F, Viola C, et al. Direct evidence that release-stimulating alpha-7nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem. 2002;80:1071–1078.
   PubMed Web of Science ®Google Scholar
• Mok MHS, Fricker A-C, Weil A, et al. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology. 2009;57:242–249.
   PubMed Web of Science ®Google Scholar
• Dobelis P, Staley KJ, Cooper DC. Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons. PLoS. 2012;7:1–6.
   Google Scholar
• Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, et al. Neurotoxicology and teratology on the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 2011;33:538–547.
   PubMed Web of Science ®Google Scholar
• Shoki O, Nobuyoshi N, Hiroshi S, et al. 3‐hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem [Internet]. 1998;70:299–307.
   PubMed Web of Science ®Google Scholar
• Zhuravlev AV, Zakharov GA, Shchegolev BF, et al. Antioxidant properties of kynurenines: density functional theory calculations. PLOS Compotational Biol [Internet]. 2016;1–31. DOI:10.1371/journal.pcbi.1005213
   Google Scholar
• Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356–1365.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, et al. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2012 [cited Dec 15];12:64–82.
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303:1–10.
   PubMed Web of Science ®Google Scholar
• Giorgini F, Guidetti P, Nguyen Q, et al. A genomic screen in yeast implicates kynurenine 3- monooxygenase as a therapeutic target for Huntington’s disease. Nat Genet. 2005;37:526–531.
   PubMed Web of Science ®Google Scholar
• Beal MF, Matson WR, Swartz KJ, et al. Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem. 1990;55:1327–1339.
   PubMed Web of Science ®Google Scholar
• Jauch D, Urbanska EM, Guidetti P, et al. Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: focus on kynurenine aminotransferases. J Neurol Sci. 1995;130:39–47.
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115:1249–1273.
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Okuno E, White RJ, et al. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci USA 1988;85:4079–4081.
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842–853.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Pearson SJ, Halket J, et al. Brain quinolinic acid in Huntington’s disease. J Neurochem. 1988;50:1959–1960.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Luthi-Carter RE, Augood SJ, et al. Neostriatal and cortical quinolinate levels are increased in early grade Huntington’s disease. Neurobiol Dis. 2004;17:455–461.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Bates GP, Graham RK, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurob. 2006;23:190–197.
   PubMed Web of Science ®Google Scholar
• Pearson SJ, Reynolds GP. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington’s disease. Neurosci Lett. 1992;144:199–201.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Reddy PH, Tagle DA, et al. Early kynurenergic impairment in Huntington’s disease and in a transgenic animal model. Neurosci Lett. 2000;283:233–235.
   PubMed Web of Science ®Google Scholar
• Sathyasaikumar KV, Stachowski EK, Amoria L, et al. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington’s disease. J Neuro. 2010;113:1416–1425.
   Google Scholar
• Gál EM, Sherman AD. Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem. 1978;30:607–613.
   PubMed Web of Science ®Google Scholar
• Vamos E, Pardutz A, Klivenyi P, et al. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci. 2009;283:21–27.
   PubMed Web of Science ®Google Scholar
• Santamaria A, Rios C, Solís-Hernández F, et al. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology. 1996;35:23–28.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Wu H, Schwarcz R. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum. Exp Neurol. 2000;163:123–130.
   PubMed Web of Science ®Google Scholar
• Zádori D, Nyiri G, Szőnyi A, et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J Neural Transm. 2011;118:865–875.
   PubMed Web of Science ®Google Scholar
• Toledo-Sherman LM, Prime ME, Mrzljak L, et al. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease. J Med Chem. 2015;58:1159–1183.
   PubMed Web of Science ®Google Scholar
• Harris CA, Miranda AF, Tanguay JJ, et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol. 1998;124:391–399.
   PubMed Web of Science ®Google Scholar
• Zwilling D, Huang S, Sathyasaikumar KV, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2012;145:863–874.
   Web of Science ®Google Scholar
• Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2010;15:1407–1413.
   Web of Science ®Google Scholar
• Szalardy L, Zadori D, Toldi J, et al. Manipulating kynurenic acid levels in the brain – on the edge between neuroprotection and cognitive dysfunction. Curr Top Med Chem. 2012;12:1797–1806.
   PubMed Web of Science ®Google Scholar
• Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203–213.
   PubMed Web of Science ®Google Scholar
• Metz R, DuHadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67:7082–7087.
   PubMed Web of Science ®Google Scholar
• Yuasa HJ, Ball HJ. Indoleamine 2,3-dioxygenases with very low catalytic activity are well conserved across kingdoms: IDOs of basidiomycota. Fungal Genet Biol [Internet]. 2013;56:98–106.
   PubMed Web of Science ®Google Scholar
• Ball HJ, Yuasa HJ, Austin CJD, et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol. 2009;41:467–471.
   PubMed Web of Science ®Google Scholar
• Yuasa HJ, Ball HJ, Fern Y, et al. Characterization and evolution of vertebrate indoleamine 2,3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol Part B. 2009;153:137–144.
   Web of Science ®Google Scholar
• van Baren N, Van den Eynde B. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015;6:1–9.
   PubMed Web of Science ®Google Scholar
• Smith AK, Simon J, Gustafson E, et al. Association of a polymorphism in the indoleamine-2,3- dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry [Internet]. 2012;17:781–789. Available from: http://www.nature.com/mp/journal/v17/n8/abs/mp201167a.html
   PubMed Web of Science ®Google Scholar
• Munn D, Zhou M, Attwood J, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science [Internet]. 1998;281:1191–1193. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9712583
   PubMed Web of Science ®Google Scholar
• Badawy AA-B, Namboodiri AMA, Moffett JR. The end of the road for the tryptophan depletion concept in pregnancy and infection. Clin Sci. 2016;130:1327–1333.
   PubMed Web of Science ®Google Scholar
• Yeung AWS, Terentis AC, King NJC, et al. Role of indoleamine 2,3-dioxygenase in health and disease. Clin Sci. 2015;129:601–672.
   PubMed Web of Science ®Google Scholar
• Baban B, Chandler P, Sharma M, et al. IDO activates regulatory T cells and blocks their conversion into TH17-like T cells. J Immunol. 2009;183:2475–2483.
   PubMed Web of Science ®Google Scholar
• Sharma MD, Huang L, Choi J-H, et al. An inherently bi-functional subset of FOxp3+ T helper cells is controlled by the transcription factor Eos. Immunitiy. 2013;38:998–1012.
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–642.
   PubMed Web of Science ®Google Scholar
• Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase – expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196:447–457.
   PubMed Web of Science ®Google Scholar
• Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol. 2010;182:7509–7517.
   Web of Science ®Google Scholar
• Liu H, Huang L, Bradley J, et al. GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell Biol. 2014;34:428–438.
   PubMed Web of Science ®Google Scholar
• Wang X-F, Wang H-S, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289:42–48.
   PubMed Web of Science ®Google Scholar
• El-Zaatari M, Chang Y, Zhang M, et al. Tryptophan catabolism restricts IFN-γ−expressing neutrophils and clostridium difficile immunopathology. J Immunol. 2014;193:807–816.
   PubMed Web of Science ®Google Scholar
• Boasso A, Herbeuval J-P, Hardy AW, et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Immunobilologyology. 2007;109:3351–3360.
   Google Scholar
• Gaelings L, Söderholm S, Bugai A, et al. Regulation of kynurenine biosynthesis during influenza virus infection. FEBS J. 2017;284:222–236.
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen H, Wen Q, et al. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:695–701.
   PubMed Web of Science ®Google Scholar
• Kwidzinski E, Aktas O, Richter D, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005;19:1–19.
   PubMed Web of Science ®Google Scholar
• Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006;18:220–225.
   PubMed Web of Science ®Google Scholar
• Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J Neural Transm. 2002;109:181–189.
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Brew BJ, Noonan CE, et al. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395–404.
   PubMed Web of Science ®Google Scholar
• Campesan S, Green EW, Breda C, et al. The kynurenine pathway modulates neurodegeneration in a drosophila model of Huntington’s disease. Curr Biol. 2011;21:961–966.
   PubMed Web of Science ®Google Scholar
• Mazarei G, Budac DP, Lu G, et al. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp Neurol J. 2013;249:144–148.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neuro. 1999;11:3857–3863.
   PubMed Web of Science ®Google Scholar
• Stone TW, Forrest CM, Stoy N, et al. Involvement of kynurenines in Huntington’s disease and stroke-induced brain damage. J Neu. 2012;119:261–274.
   Google Scholar
• Wurster CD, Ludolph AC. Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord. 2018;11:1–19.
   Web of Science ®Google Scholar
• Tabrizi S, Leavitt B, Kordasiewicz H, et al. Effects of IONIS-HTTRx in patients with early Huntington’s disease, results of the first HTT-lowering drug trial (CT.002). Neurology. 2018;90:(15 Suppl.).
   Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E, et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res. 1993;49:151–165.
   PubMed Web of Science ®Google Scholar
• Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci. 2004;29:11–17.
   PubMed Web of Science ®Google Scholar
• Yang G, Lu X, Yuan L. Biochimica et biophysica acta LncRNA: a link between RNA and cancer. BBA Gene Regul Mech [Internet]. 2014;1839:1097–1109.
   Google Scholar
• Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111:3257–3266.
   PubMed Web of Science ®Google Scholar
• Reniers J, Meinguet C, Moineaux L, et al. Synthesis and inhibition study of monoamine oxidase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by 3,8-substituted 5H-indeno[1,2-c]pyridazin-5-one derivatives. Eur J Med Chem. 2011;46:6104–6111.
   PubMed Web of Science ®Google Scholar
• Jiang T, Sun Y, Yin Z, et al. Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med Chem. 2015;7:185–201.
   PubMed Web of Science ®Google Scholar